A Closer Look: Sun’s Settlement With Pfizer May Cloud Its Ability For Large Buyouts
This article was originally published in PharmAsia News
With a large chunk of its cash reserves spent to settle the Protonix patent case, India’s Sun Pharma may no longer be in position to follow its inorganic growth plans.
You may also be interested in...
How risky are at-risk launches of generic products?
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.